The Pharma Data

APRIL 7, 2021

Yet as challenging as 2020 was, it also brought us –Sanofi and the pharmaceutical industry– closer to our purpose than at any other time in living memory ,” said Hudson. Thirty of Sanofi’s medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria and cancer.

Vaccine 52

Vaccine Packaging Disease Treatment 52

The Pharma Data

DECEMBER 1, 2020

Many neglected tropical diseases (NTDs) result from diverse types of interactions and often complex cycles of transmission between humans and animals, both vertebrates and invertebrates, and changing social and environmental conditions.

Disease 52

Disease Vaccine Government Science 52

New Drug Approvals

JANUARY 31, 2024

In addition to hyperlipidemia and type 2 diabetes, a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) has occurred. The present invention addresses these needs for new treatment methods, compounds, and pharmaceutical compositions. Current drugs that treat hyperlipidemia (e.g., Skjaeret, et al.

Treatment 52

Treatment Disease Pharmaceuticals Drugs 52

The Pharma Data

FEBRUARY 22, 2022

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “ We are making great progress on our ambition to be zero carbon across our global operations by the end of 2025 and carbon negative across our entire value chain by 2030. AstraZeneca is an established leader in respiratory care with a 50-year heritage.

Science 52

Science Disease Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Premier Consulting Blog

MAY 4, 2023

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. At Premier Consulting, our team of pharmaceutical regulatory experts is helping clients understand the changing regulatory landscape related to ophthalmic drugs and devices. The global ophthalmic drugs market size was valued at $33.81

FDA 52

FDA Packaging Regulations Compliance 52

The Pharma Data

MARCH 2, 2021

Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. Obesity is a complex chronic disease that requires long-term management. It is among the leading risk factors for several cardio-metabolic diseases, such as heart disease, ischemic stroke, liver diseases incl.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Drug Target Review

OCTOBER 1, 2024

Following clinical practice, I transitioned to the world of pharmaceutical companies which also had its challenges as I had to learn everything from scratch and use my experience and knowledge differently. Being a doctor means giving courage and hope day in, day out to those experiencing illness.

Doctors 97

Doctors Therapies Science Pharma Companies 97

Vial

APRIL 18, 2024

Yet, hereditary and age-related retinal diseases present challenges, often leading to progressive vision loss and potential blindness. Market research indicates significant growth in the ophthalmic clinical trials market, driven by increased disease prevalence, demand for ocular treatments, and rising research funding.

Clinical Trials 52

Clinical Trials Trials Treatment Clinical Research 52

The Pharma Data

SEPTEMBER 15, 2020

More sensitive than traditional Pap cytology, this test allows clinicians to determine which HPV-positive women require further diagnostic procedures to prevent disease progression. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

Vial

MAY 20, 2024

Within each of these, pharmaceutical and biotech sponsors are supported by preclinical and clinical contract research organizations (CROs) in clinical trials across various indications. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO? over this period.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

FEBRUARY 24, 2022

– Heart failure represents a significant, growing disease burden in the U.S., with more than 8 million cases expected by 2030. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. vice president, Product Development, Lilly.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

MARCH 11, 2021

And at Pharmaceuticals, we are seeing success in our late-stage pipeline and are very well positioned with the investments we are making in our future. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. through 2023.

Science 52

Science Pharmaceuticals Licensing Licensing 52

DrugBank

FEBRUARY 19, 2025

The application of Artificial Intelligence (AI) in drug discovery is rapidly transforming the pharmaceutical industry, offering opportunities to accelerate the identification of novel therapeutic targets, optimize molecule design, and enhance clinical trial efficiency. billion in 2023 to $7.9

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

NOVEMBER 22, 2020

This patent completes the Ezeprogind related patents granted in the USA for composition of matter (US 9,562,018) and therapeutic uses in the treatment of Alzheimer’s and Parkinson’s diseases (US 10,537,569). Alzprotect is committed to the development of innovative therapeutic solutions in the field of neurodegenerative diseases.

Drugs 40

Drugs Disease Clinical Trials Licensing 40

The Pharma Data

AUGUST 5, 2021

percent to 2.577 billion euros, burdened by currency effects of 153 million euros / Crop Science posts strong sales growth, earnings impacted by higher costs and currency effects / Pharmaceuticals reports significant recovery after COVID-19 effects in prior year / Consumer Health continues growth momentum / Core earnings per share rise by 1.3

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

MAY 4, 2021

Lilly will donate both baricitinib (4 mg tablet) as well as bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together – providing options to treat COVID-19 patients at different stages of the disease. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country. .”

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. Between the technical uncertainty and the horrendous PR, pharmaceutical companies had little interest in adopting molecular farming technologies. The total global bioprocessing capacity was estimated at 17.4

Engineering 87

Engineering Vaccine Production RNA 87

Vial

FEBRUARY 8, 2024

To advance new therapies, pharmaceutical, biotech, and medical device companies engage contract research organizations (CROs) for their know-how in navigating the complex landscape of drug development and regulatory pathways and to run clinical trials. billion in 2030. How do CROs solve the challenges of managing clinical trials?

Clinical Trials 52

Clinical Trials Trials Clinical Research Research 52

The Pharma Data

APRIL 27, 2021

Pharmaceuticals. First-quarter 2021 Pharmaceutical sales increased 3.8% Rare Disease. Others Rare Disease. Total Rare Disease. In the first quarter, Rare Disease sales increased 4.4% Globally, diagnosis of the disease and product awareness remain impacted by the COVID-19 environment. . Change at CER.

Vaccine 52

Vaccine Production FDA Disease 52

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. MHRA launched the pilot in late 2023 and ultimately chose eight products with different technologies that address life-threatening diseases with no equivalent solutions that also support the U.K.’s s Life Sciences Vision.

Regulations 40

Regulations International Government Production 40

The Pharma Data

NOVEMBER 5, 2020

Regeneron Pharmaceuticals, Inc. This quarter we had robust top- and bottom-line growth driven by EYLEA in retinal diseases and Dupixent in atopic dermatitis and asthma. About Regeneron Pharmaceuticals, Inc. Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Production 40

Production Trials FDA FDA Approval 40

The Pharma Data

FEBRUARY 8, 2021

Pharmaceuticals. Fourth-quarter 2020 Pharmaceutical sales increased 2.4% Fourth-quarter 2020 Pharmaceutical sales increased 2.4% In 2020, Pharmaceuticals sales increased 3.1% Rare Disease. Others Rare Disease. Total Rare Disease. In the fourth quarter, Rare Disease sales increased 3.0%

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

FEBRUARY 4, 2021

Pharmaceuticals. Fourth-quarter 2020 Pharmaceutical sales increased 2.4% Fourth-quarter 2020 Pharmaceutical sales increased 2.4% In 2020, Pharmaceuticals sales increased 3.1% Rare Disease. Others Rare Disease. Total Rare Disease. In the fourth quarter, Rare Disease sales increased 3.0%

Vaccine 52

Vaccine Production FDA Therapies 52

The Pharma Data

DECEMBER 18, 2020

billion: Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation (IFFIm), to be paid from 2021 to 2030. Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world’s children against some of the world’s deadliest diseases.

Vaccine 52

Vaccine Government International Virus 52

Agency IQ

JUNE 16, 2023

See Asbestos Disease Awareness Organization v. The standards would begin with model year 2027 heavy-duty vehicles, with stringency levels through model year 2030 and beyond. The standards will begin with model year 2027 light-duty vehicles, with stringency levels set at least through model year 2030. 19-CV-03807.

Regulations 40

Regulations Compliance Production Science 40

Codon

FEBRUARY 23, 2025

Because of PEPFAR’s effectiveness, the United Nations (UN) set an ambitious goal in 2022 to end HIV transmission and eliminate AIDS-related deaths by 2030. In 2024, the pharmaceutical company Gilead announced that a single injection of lenacapavir protected 96 to 100 percent of recipients from HIV for up to six months.

Clinical Trials 70

Clinical Trials Virus Vaccine DNA 70